Lysis of cancer cells by autologous T cells in breast cancer pleural effusates treated with anti-EpCAM BiTE antibody MT110

Breast Cancer Research and Treatment

Volumn 117, Issue 3, 2009, Pages 471-481

  Witthauer, Juliane ^a   Schlereth, Bernd ^b   Brischwein, Klaus ^b   Winter, Hauke ^c   Funke, Ilona ^d   Jauch, Karl Walter ^a   Baeuerle, Patrick ^b   Mayer, Barbara ^a,e  

^a UNIVERSITY OF MUNICH   (Germany)

^b MICROMET AG   (Germany)

^c Zentrum für Pneumologie und Thoraxchirurgie   (Germany)

^d Chirurgische Klinik Dr Rinecker   (Germany)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Bispecific antibody; Breast cancer; CD3; EpCAM; Ex vivo therapy; Malignant pleural effusion; MT110

Indexed keywords

ANTINEOPLASTIC AGENT; CD3 ANTIGEN; EPITHELIAL CELL ADHESION MOLECULE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; MONOCLONAL ANTIBODY; MT 110; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOKINE RELEASE; CYTOLYSIS; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; PLEURA EFFUSION; PRIORITY JOURNAL; T LYMPHOCYTE;

ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CELL ADHESION MOLECULES; CYTOKINES; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE ACTIVATION; PLEURAL EFFUSION, MALIGNANT; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES;

EID: 70349573782     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-0185-0     Document Type: Article

References (54)

1. G Antunes E Neville J Duffy N Ali 2003 BTS guidelines for the management of malignant pleural effusions Thorax 58 Suppl II ii29 ii38 10.1136/thorax.58. suppl-2.ii29 12728148
2. Neragi-Miandoab S (2008) Surgical and other invasive approaches to recurrent pleural effusion with malignant etiology. Support Care Cancer. doi: 10.1007/s00520-008-0405-5
3. VB Antony R Loddenkemper P Astoul, et al. 2001 Management of malignant pleural effusions Eur Respir J 18 402 419 10.1183/09031936.01.00225601 11529302 10.1183/09031936.01.00225601 1:STN:280:DC%2BD3MvoslalsQ%3D%3D (Pubitemid 32776419)
4. N Barbetakis T Antoniadis C Tsilikas 2004 Results of chemical pleurodesis with mitoxantrone in malignant pleural effusion from breast cancer World J Surg 2 16 10.1186/1477-7819-2-16 10.1186/1477-7819-2-16 (Pubitemid 39112098)
5. V Steger U Mika T Heikki, et al. 2007 Who gains most? A 10-year experience with 611 thoracoscopic talc pleurodeses Ann Thorac Surg 83 1940 1945 10.1016/j.athoracsur.2007.02.061 17532375 10.1016/j.athoracsur.2007.02.061 (Pubitemid 46782679)
6. DE Danner JT Gmelich 1975 A comparative study of tumor cells from metastatic carcinoma of the breast in effusions Acta Cytol 19 6 509 518 55031 1:STN:280:DyaE287gvVajsw%3D%3D
7. FJ Van de Molengraft GP Vooijs 1988 The interval between the diagnosis of malignancy and the development of effusions, with reference to the role of cytologic diagnosis Acta Cytol 32 183 187 3348059
8. EL Wiley JV Roenn 1990 Metastatic breast carcinoma in pleural fluid Acta Cytol 34 169 174 2321450 1:STN:280:DyaK3c3gvFCgug%3D%3D
9. BA Price H Ehya JH Lee 1992 Significance of pericellular lacunae in cell blocks of effusions Acta Cytol 36 333 337 1580117 1:STN:280:DyaK383lsVGntg%3D%3D
10. B Davidson B Risberg G Kristensen, et al. 1999 Detection of cancer in effusions from patients diagnosed with gynaecological malignancies Virchows Arch 435 43 49 10.1007/s004280050393 10431845 10.1007/s004280050393 1:CAS:528:DyaK1MXktVSks70%3D (Pubitemid 29346741)
11. B Davidson 2004 Malignant effusions: from diagnosis to biology Diagn Cytopathol 31 246 254 10.1002/dc.20133 15452897 10.1002/dc.20133 (Pubitemid 39314820)
12. M Dieterich SN Goodman RR Rojas-Corona, et al. 1994 Multivariate analysis of prognostic features in malignant pleural effusions from breast cancer patients Acta Cytol 38 945 952 7992584 1:STN:280:DyaK2M%2FosVOisQ%3D%3D
13. B Risberg B Davidson HP Dong JM Nesland A Berner 2000 Flow cytometric immunophenotyping of serous effusions and peritoneal washings: comparison with immunocytochemistry and morphological findings J Clin Pathol 53 513 517 10.1136/jcp.53.7.513 10961174 10.1136/jcp.53.7.513 1:STN:280: DC%2BD3cvhtlahtg%3D%3D (Pubitemid 30432108)
14. AL Filho VA Alves CT Kanamura, et al. 2002 Identification of the primary site of metastatic adenocarcinoma in serous effusions Acta Cytol 46 651 658
15. P Lissoni M Mandala G Curigliano, et al. 2001 Progress report on the palliative therapy of 100 patients with neoplastic effusions by intracavitary low-dose interleukin-2 Oncology 60 308 312 10.1159/000058525 11408797 10.1159/000058525 1:CAS:528:DC%2BD3MXlsFShtLc%3D (Pubitemid 32623444)
16. P Lissoni S Barni G Tancini, et al. 1995 Intracavitary therapy of neoplastic effusions with cytokines: comparison among interferon α, β and interleukin-2 Support Care Cancer 3 78 80 10.1007/BF00343925 7697307 10.1007/BF00343925 1:STN:280:DyaK2M3htFeqtA%3D%3D
17. A Sandler 2007 Bevacizumab in non-small lung cancer Clin Cancer Res 13 4613 4616 10.1158/1078-0432.CCR-07-0647 10.1158/1078-0432.CCR-07-0647 (Pubitemid 47219734)
18. H Iwata 2007 Perspective of trastuzumab treatment Breast Cancer 14 150 155 10.2325/jbcs.955 17485899 10.2325/jbcs.955
19. Beano A, Signorino E, Evangelista A, Brusa D, Mistrangelo M (2008) Correlation between NK function and response to trastuzumab in metastatic breast cancer patients. J Transl Med. doi: 10.1186/1479-5876-6-25 (Pubitemid 351803896)
20. P Carter 2001 Improving the efficacy of antibody-based cancer therapies Nat Rev Cancer 1 118 129 10.1038/35101072 11905803 10.1038/35101072 1:CAS:528:DC%2BD38XlvF2qsLw%3D
21. P Kufer R Lutterbuese PA Baeuerle 2004 A revival of bispecific antibodies Trends Biotechnol 22 238 244 10.1016/j.tibtech.2004.03.006 15109810 10.1016/j.tibtech.2004.03.006 1:CAS:528:DC%2BD2cXjtl2lt7g%3D (Pubitemid 38515741)
22. E Wolf R Hofmeister P Kufer B Schlereth PA Baeuerle 2005 BITEs: bispecific antibody constructs with unique anti-tumor activity Drug Discov Today 10 1237 1244 10.1016/S1359-6446(05)03554-3 16213416 10.1016/S1359-6446(05) 03554-3 1:CAS:528:DC%2BD2MXhtVGgsLzK (Pubitemid 41411434)
23. T Dreier G Lorenczewski C Brandl, et al. 2002 Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single chain bispecific antibody Int J Cancer 100 690 697 10.1002/ijc.10557 12209608 10.1002/ijc.10557 1:CAS:528:DC%2BD38XlvFKgsr0%3D (Pubitemid 34832980)
24. K Brischwein B Schlereth B Guller, et al. 2006 MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors Mol Immunol 43 1129 1143 10.1016/j.molimm.2005.07.034 16139892 10.1016/j.molimm.2005.07.034 1:CAS:528:DC%2BD28XjsFKntA%3D%3D (Pubitemid 43063166)
25. K Brischwein L Parr S Pflanz, et al. 2007 Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class J Immunother 30 798 807 18049331 10.1097/CJI.0b013e318156750c 1:CAS:528:DC%2BD2sXhtlGqs7fM (Pubitemid 350295358)
26. P Hoffmann R Hofmeister K Brischwein, et al. 2005 Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct Int J Cancer 115 98 104 10.1002/ijc.20908 15688411 10.1002/ijc.20908 1:CAS:528:DC%2BD2MXjslejur0%3D (Pubitemid 40559673)
27. S Offner R Hofmeister A Romaniuk P Kufer PA Baeuerle 2006 Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells Mol Immunol 43 763 771 10.1016/j.molimm. 2005.03.007 16360021 10.1016/j.molimm.2005.03.007 1:CAS:528:DC%2BD2MXhtlWhsrbP (Pubitemid 41785405)
28. M Amann K Brischwein P Lutterbuese, et al. 2008 Therapeutic window of MuS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3 Cancer Res 68 143 151 10.1158/0008-5472.CAN-07-2182 18172306 10.1158/0008-5472.CAN-07-2182 1:CAS:528:DC%2BD1cXos12m
29. B Schlereth I Fichtner G Lorenczewski, et al. 2005 Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct Cancer Res 65 2882 2889 10.1158/0008-5472.CAN-04-2637 15805290 10.1158/0008-5472.CAN-04-2637 1:CAS:528:DC%2BD2MXjtVeqt78%3D (Pubitemid 40490092)
30. B Schlereth P Kleindienst I Fichtner, et al. 2006 Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for Murine CD3 Cancer Immunol Immunother 55 785 796 10.1007/s00262-005-0082-x 16187083 10.1007/s00262-005-0082-x 1:CAS:528:DC%2BD28XivFShur8%3D
31. P Ruf H Lindhofer, et al. 2001 Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody Blood 98 2526 2534 10.1182/blood.V98.8.2526 11588051 10.1182/blood.V98.8.2526 1:CAS:528: DC%2BD3MXnslCqs7Y%3D
32. S Morecki H Lindhofer E Yacovlev Y Gelfand S Slavin 2006 Use of trifunctional bispecific antibodies to prevent graft versus host disease induced by allogeneic lymphocytes Blood 107 1564 1569 10.1182/blood-2005-07-2738 16234351 10.1182/blood-2005-07-2738 1:CAS:528:DC%2BD28XhsFemt7g%3D (Pubitemid 43242395)
33. Morecki S, Lindhofer H, Yacovlev E, Gelfand Y, Ruf P (2008) Induction of a long-lasting antitumor immunity by concomitant cell therapy with allogeneic lymphocytes and trifunctional bispecific antibody. Exp Hematol. doi: 10.1016/l.exphem.2008.03.005
34. A Burges P Wimberger C Kümper V Gorbounova H Sommer B Schmalfeldt 2007 Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study Clin Cancer Res 13 3899 3905 10.1158/1078-0432.CCR-06-2769 17606723 10.1158/1078-0432.CCR-06-2769 1:CAS:528:DC%2BD2sXntFymtrc%3D (Pubitemid 47037597)
35. Web article available on http://www.micromet.de
36. TM Elsheikh JL Kirkpatrick HH Wu 2006 Comparison of ThinPrep and cytospin preparations in the evaluation of exfoliative cytology specimens Cancer 108 3 144 149 10.1002/cncr.21841 16550571 10.1002/cncr.21841 (Pubitemid 43911809)
37. A Al-Nafussi PJ Carder 1989 Monoclonal antibodies in the cytodiagnosis of serous effusions Cytopathology 1 119 128 10.1111/j.1365-2303.1990.tb00336.x 10.1111/j.1365-2303.1990.tb00336.x
38. SM Hsu L Raine H Fanger 1981 Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures J Histochem Cytochem 29 4 577 580 6166661 1:STN:280:DyaL3M3ktVKrug%3D%3D
39. W Xiang P Wimberger T Dreier J Diebold D Mayr PA Baeuerle, et al. 2003 Cytotoxic activity of novel human monoclonal antibody MT201 against primary ovarian tumor cells J Cancer Res Clin Oncol 129 6 341 348 10.1007/s00432-003- 0438-6 12819960 10.1007/s00432-003-0438-6 1:CAS:528:DC%2BD3sXlsVSksrY%3D (Pubitemid 36963196)
40. YC Lee RW Light 2004 Management of malignant pleural effusions Respirology 9 148 156 10.1111/j.1440-1843.2004.00566.x 15182263 10.1111/j.1440-1843.2004.00566.x (Pubitemid 38937386)
41. JP Janssen G Collier P Astoul, et al. 2007 Safety of pleurodesis with talc poudrage in malignant pleural effusion: a prospective cohort study Lancet 369 1535 1539 10.1016/S0140-6736(07)60708-9 17482984 10.1016/S0140-6736(07) 60708-9 (Pubitemid 46670303)
42. PA Baeuerle O Gires 2007 EpCAM (CD326) finding its role in cancer Br J Cancer 96 417 423 10.1038/sj.bjc.6603494 17211480 10.1038/sj.bjc.6603494 1:CAS:528:DC%2BD2sXhtlKjtrg%3D (Pubitemid 46215211)
43. MA Chaudry K Sales P Ruf H Lindhofer MC Winslet 2007 EpCAM an immunotherapeutic target for gastrointestinal malignancy: current experience and future challenges Br J Cancer 96 1013 1019 10.1038/sj.bjc.6603505 17325709 10.1038/sj.bjc.6603505 1:CAS:528:DC%2BD2sXjsleksrk%3D (Pubitemid 46608303)
44. P Wimberger W Xiang D Mayr, et al. 2003 Efficient tumor cell lysis by autologous, tumor-resident T lymphocytes in primary ovarian cancer samples by an EpCAM-/CD3-bispecific antibody Int J Cancer 105 241 248 10.1002/ijc.11056 12673686 10.1002/ijc.11056 1:CAS:528:DC%2BD3sXjt12mt78%3D (Pubitemid 36505328)
45. TF Gajewski Y Meng H Harlin 2006 Immune suppression in the tumor microenvironment J Immunother 29 233 240 10.1097/01.cji.0000199193.29048.56 16699366 10.1097/01.cji.0000199193.29048.56 1:CAS:528:DC%2BD28XksFKgsbg%3D (Pubitemid 44297291)
46. TF Gajewski 2006 Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment Clin Cancer Res 12 2326s 2330s 10.1158/1078-0432.CCR-05-2517 16609053 10.1158/1078-0432.CCR-05-2517 1:CAS:528:DC%2BD28XjtlChsb8%3D
47. M Schmitt A Schmitt P Reinhardt, et al. 2004 Opsonization with a trifunctional bispecific (αCD3 × αEpCAM) antibody results in efficient lysis in vitro and in vivo of EpCAM positive tumor cells by cytotoxic T lymphocytes Int J Oncol 25 841 848 15375531 1:CAS:528:DC%2BD2cXovFWluro%3D
48. Bargou R, Noppeney R, Schuler M et al (2006) The bi-specific T-cell enhancer (BiTE) MT103 (MEDI-538) induces clinical responses in heavily pre-treated NHL patients: update from the ongoing phase I study MT103-104. Blood (ASH Annual Meeting Abstracts) 108:Abstract 693
49. G Spizzo P Went S Dirnhofer, et al. 2004 High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer Breast Cancer Res Treat 86 207 213 10.1023/B:BREA.0000036787.59816.01 15567937 10.1023/B:BREA.0000036787.59816.01 1:CAS:528:DC%2BD2cXmt1Kqt74%3D (Pubitemid 39070963)
50. P Went A Lugli S Meier, et al. 2004 Frequent EpCAM protein expression in human carcinoma Hum Pathol 35 122 128 10.1016/j.humpath.2003.08.026 14745734 10.1016/j.humpath.2003.08.026 1:CAS:528:DC%2BD2cXntVKlsw%3D%3D (Pubitemid 38133932)
51. CG Rao D Chianese GV Doyle, et al. 2005 Expression of epithelial cell adhesion molecule in carcinoma cells present in blood and primary and metastatic tumors Int J Oncol 27 49 57 15942643 1:CAS:528:DC%2BD2MXmtlKisLc%3D
52. M Al-Hajj 2007 Cancer stem cells and oncology therapeutics Curr Opin Oncol 19 61 64 17133114
53. WA Osta Y Chen K Mikhitarian, et al. 2004 EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy Cancer Res 64 5818 5824 10.1158/0008-5472.CAN-04-0754 15313925 10.1158/0008-5472.CAN- 04-0754 1:CAS:528:DC%2BD2cXmslaks74%3D (Pubitemid 39095582)
54. M Münz C Kieu B Mack B Schmitt R Zeidler O Gires 2004 The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation Oncogene 23 5748 5758 10.1038/sj.onc.1207610 15195135 10.1038/sj.onc.1207610 (Pubitemid 39093020)